

## SEL-COV

Selisistat as potential treatment for COVID-19 infection by modulation of SIRT1

|                                 |                                                                  |                        |               |
|---------------------------------|------------------------------------------------------------------|------------------------|---------------|
| <b>Programm / Ausschreibung</b> | Emergency-Call, Emergency-Call Coronavirus 2020, KLIPHA-Covid_19 | <b>Status</b>          | abgeschlossen |
| <b>Projektstart</b>             | 01.05.2020                                                       | <b>Projektende</b>     | 30.04.2021    |
| <b>Zeitraum</b>                 | 2020 - 2021                                                      | <b>Projektlaufzeit</b> | 12 Monate     |
| <b>Keywords</b>                 |                                                                  |                        |               |

### Projektbeschreibung

AOP Orphan aims to conduct a clinical trial in patients suffering from COVID-19 in order to determine the safety and efficacy of Selisistat, a highly selective inhibitor of silencing information regulator T1 (SIRT1). Selisistat (Ex-527) targets the angiotensin-converting enzyme 2 (ACE2), the main SARS-CoV-2 receptor required for entry and effective replication of the virus in the host cell. Since the safety of Selisistat (racemic mixture of S-[active]- and R-[inactive] enantiomers) was investigated in several clinical trials, the drug was found to be safe and well tolerated in healthy subjects and patients. AOP Orphan aims to conduct a phase II study with the already available drug (racemic mixture in an oral tablet). The clinical trial will be initiated with 40 patients for a safety review to evaluate the use of Selisistat in COVID-19. In parallel, AOP plans to optimize the drug formulation (active S-enantiomer without the R-[inactive] enantiomer) for COVID-19 treatment. The optimized drug candidate will be evaluated in the second part of the phase II trial for safety and efficacy.

### Projektpartner

- AOP Orphan Pharmaceuticals GmbH